BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

672 related articles for article (PubMed ID: 17314225)

  • 1. Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy.
    Carr JM; Cheney KM; Coolen C; Davis A; Shaw D; Ferguson W; Chang G; Higgins G; Burrell C; Li P
    J Clin Microbiol; 2007 Apr; 45(4):1288-97. PubMed ID: 17314225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative detection of human immunodeficiency virus type 1 (HIV-1) proviral DNA in peripheral blood mononuclear cells by SYBR green real-time PCR technique.
    Gibellini D; Vitone F; Schiavone P; Ponti C; La Placa M; Re MC
    J Clin Virol; 2004 Apr; 29(4):282-9. PubMed ID: 15018857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
    Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
    N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy.
    Vitone F; Gibellini D; Schiavone P; Re MC
    J Clin Virol; 2005 Jul; 33(3):194-200. PubMed ID: 15911440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
    J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.
    Re MC; Vitone F; Biagetti C; Schiavone P; Alessandrini F; Bon I; de Crignis E; Gibellini D
    Clin Microbiol Infect; 2010 Jun; 16(6):640-6. PubMed ID: 19732081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of total and integrated HIV-1 DNA in peripheral CD4 lymphocytes and monocytes after long treatment with HAART.
    Calcaterra S; Cappiello G; Di Caro A; Garbuglia AR; Benedetto A
    J Infect; 2001 Nov; 43(4):239-45. PubMed ID: 11869061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups.
    Dornadula G; Nunnari G; Vanella M; Roman J; Babinchak T; DeSimone J; Stern J; Braffman M; Zhang H; Pomerantz RJ
    J Infect Dis; 2001 Jun; 183(11):1682-7. PubMed ID: 11343220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
    Soulié C; Fourati S; Lambert-Niclot S; Malet I; Wirden M; Tubiana R; Valantin MA; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2010 Apr; 65(4):749-51. PubMed ID: 20150182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of cell-free and cell-associated peripheral blood human immunodeficiency virus type 1 RNA response to antiretroviral therapy.
    Romano L; Venturi G; Catucci M; De Milito A; Valensin PE; Zazzi M
    J Infect Dis; 1999 Feb; 179(2):361-6. PubMed ID: 9878019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.
    Nicastri E; Tommasi C; Abbate I; Bonora S; Tempestilli M; Bellagamba R; Viscione M; Rozera G; Gallo AL; Ivanovic J; Amendola A; Pucillo L; Di Perri G; Capobianchi MR; Narciso P
    Antivir Ther; 2011; 16(6):797-803. PubMed ID: 21900711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of HIV-1 in the cervicovaginal secretions and blood of pregnant and nonpregnant women.
    Shaheen F; Sison AV; McIntosh L; Mukhtar M; Pomerantz RJ
    J Hum Virol; 1999; 2(3):154-66. PubMed ID: 10413367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
    Goicoechea M; Smith DM; Liu L; May S; Tenorio AR; Ignacio CC; Landay A; Haubrich R
    J Infect Dis; 2006 Jul; 194(1):29-37. PubMed ID: 16741879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
    Chun TW; Carruth L; Finzi D; Shen X; DiGiuseppe JA; Taylor H; Hermankova M; Chadwick K; Margolick J; Quinn TC; Kuo YH; Brookmeyer R; Zeiger MA; Barditch-Crovo P; Siliciano RF
    Nature; 1997 May; 387(6629):183-8. PubMed ID: 9144289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy.
    Masquelier B; Taieb A; Reigadas S; Marchou B; Cheneau C; Spire B; Charpentier C; Leport C; Raffi F; Chêne G; Descamps D;
    J Antimicrob Chemother; 2011 Jul; 66(7):1582-9. PubMed ID: 21525020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus type 1 (HIV-1) proviral DNA load in purified CD4+ cells by LightCycler real-time PCR.
    Kabamba-Mukadi B; Henrivaux P; Ruelle J; Delferrière N; Bodéus M; Goubau P
    BMC Infect Dis; 2005 Mar; 5():15. PubMed ID: 15780144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in proviral DNA load between HIV-1- and HIV-2-infected patients.
    Gueudin M; Damond F; Braun J; Taïeb A; Lemée V; Plantier JC; Chêne G; Matheron S; Brun-Vézinet F; Simon F
    AIDS; 2008 Jan; 22(2):211-5. PubMed ID: 18097223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens.
    Sarmati L; Parisi SG; Nicastri E; d'Ettorre G; Andreoni C; Dori L; Gatti F; Montano M; Buonomini AR; Boldrin C; Palù G; Vullo V; Andreoni M
    J Med Virol; 2007 Jul; 79(7):880-6. PubMed ID: 17516532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of genetic diversity reduction in the HIV-1 integrated proviral LTR sequence population during successful combination therapy.
    Ibáñez A; Clotet B; Martínez MA
    Virology; 2001 Mar; 282(1):1-5. PubMed ID: 11259184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.